Litcius/Paper detail

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Jeroen van Dorp, Christodoulos Pipinikas, Britt B.M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Antoine G. van der Heijden, Nitzan Rosenfeld, Bas W.G. van Rhijn, Greg Jones, Michiel S. van der Heijden

2023Nature Medicine78 citationsDOIOpen Access PDF

Topics & Concepts

IpilimumabNivolumabMedicineCohortInternal medicineHazard ratioOncologyBladder cancerUrologyCancerConfidence intervalImmunotherapyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies